{"id":"ugn-103","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3663409","moleculeType":"Small molecule","molecularWeight":"422.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"UGN-103 works by selectively targeting and killing cancer cells in the bladder, while sparing healthy cells. This is achieved through a unique mechanism that involves the disruption of the cancer cells' ability to repair DNA damage. As a result, the cancer cells undergo programmed cell death, or apoptosis.","oneSentence":"UGN-103 is a synthetic, small molecule that targets the urothelial cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:08.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle invasive bladder cancer"}]},"trialDetails":[{"nctId":"NCT06331299","phase":"PHASE3","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2024-08-29","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["UGN-103 (mitomycin) for intravesical solution"],"phase":"phase_3","status":"active","brandName":"UGN-103","genericName":"UGN-103","companyName":"UroGen Pharma Ltd.","companyId":"urogen-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"UGN-103 is a small molecule being studied in a Phase 3 clinical trial for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. The study, NCT06331299, is evaluating the efficacy and safety of UGN-103 in patients with this condition.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}